Esophageal cancer
Conditions
Interventions
It is conducted as an accompanying study of Clinical Phase I / II trial of Weekly Docetaxel Therapy for Simultaneous Radiation in FP Refractory / Intolerance Example of Esophageal Cancer, and treatmen
Sponsors
The Jikei university school of medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Target disease; FP therapy refractory / progression-free, Recurrent esophageal cancer Esophageal cancer Standard surgical chemotherapy (FP therapy) was performed and recurrence within 9 months after esophageal cancer surgery postoperative chemotherapy (FP therapy) after esophageal cancer surgery and recurrence within 9 months Esophageal Cancer Standard case of preoperative chemotherapy (FP therapy) but judged that there is no indication for surgery Case of FP progression intolerance (reduced renal function, platinum allergy) in advanced esophageal cancer Example of recurrence of early metastasis outside irradiation in cases after combined chemoradiotherapy for FP Patients who are registered in clinical studies of 'Clinical Phase I / II Studies of Weekly Docetaxel Therapy in Combined Radiation in Epilepsy FP Refractory / Intolerance cases in Esophageal Cancer'. It is impossible to participate in this research only due to the characteristics of the test. In case 2) Regarding participation in research including provision of samples, agreement by text has been obtained from the patient himself.
Exclusion criteria
Exclusion criteria: 1) Patients receiving transfusions, blood products and hematopoietic factor preparations such as G-CSF within 14 days before registration 2) Cases with infections or diseases requiring systemic administration of antibiotics, antifungal agents 3) Cases with complications as shown below Control poor hypertension, diabetes Severe lung disease (interstitial pneumonia, pulmonary fibrosis, advanced emphysema, etc.) Liver failure Gastrointestinal bleeding that requires treatment 4) Patients with marked electrocardiogram abnormality or cases with clinically problematic heart disease Cases with congestive heart failure, symptomatic coronary artery disease, poorly controlled arrhythmia, a history of myocardial infarction that developed within the last 12 months, etc 5) Cases with psychiatric disorder judged by the investigator or test sharing doctor to have acquired consent or adversely affect test performance Control malfunctioning epileptic seizures, central nervous system disorders, etc. 6) Cases with moderate or more ascites (above the pelvic cavity) or with large pleural effusions 7) Cases with brain metastasis or suspected brain metastasis from clinical symptoms 8) Cases with extensive bone metastases 9) Cases with active duplicated cancers 10) HIV antibody positive cases 11) Patients who received treatment with another study drug within 4 weeks before registration of this study or participate in other clinical trials (incidental study of this study "Esophageal cancer chemical radiation by genetic analysis Clinical research on susceptibility of therapy and prediction of side effects "excluding) 12) Cases judged unsuitable as subjects of the examination by the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| We investigate whether mutations / polymorphisms of ABCB1, ABCC2, SLCO1B3, CYP39A1, NEIL1 gene are predictors of tumor shrinkage effect. | — |
Countries
Japan
Contacts
Public ContactKazumi Hayashi
The Jikei University school of medicine Department of Hematology and Oncology
Outcome results
None listed